Skip to main content

HIV/AIDS

Featured Article
Conducted by researchers from RTI Health Solutions and Georgetown University, the analysis considered the cost-effectiveness and budget impact of using ibalizumab, a first-in-class, long-acting,…
“The review demonstrated heterogeneity in approaches to evaluate costs and outcomes for STI/HIV control programs,” researchers wrote.

Insights

Jenn Zerbato, PhD, post-doctoral research fellow, Peter Doherty Institute for Infection and Immunity, breaks down why HIV RNA could serve as a better measure of efficient latency reversal in both pre-clinical and clinical assessment of latency…
Max Lataillade, DO, head of global research strategy, ViiV Healthcare, discusses the findings of the BRIGHTE study that demonstrated a significant decrease in HIV-1 RNA levels among patients treated with fostemsavir, a first-in-class investigational…
While great strides have been made in treating people with HIV over the past few decades, the US Preventive Task Force is strongly recommending PrEP for anyone at risk to help prevent the spread of the disease with which approximately 1.1 million…
A number of barriers are keeping patients from gaining access to cheaper, generic versions of HIV treatment medications.

Interactive Features

Ed Pezalla, MD, CEO, Enlightenment Bioconsult LLC, speaks about the barriers to preventive HIV care, pinpoints how payers can reach at-risk populations, and reviews the US Preventive Services Task Force’s measures requiring health plans to provide…
Back to Top